Nordea Investment Management AB Boosts Stock Position in Zoetis Inc. $ZTS

Nordea Investment Management AB boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 79.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,932,787 shares of the company’s stock after buying an additional 2,179,578 shares during the period. Nordea Investment Management AB’s holdings in Zoetis were worth $622,222,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the stock. Halbert Hargrove Global Advisors LLC increased its holdings in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new position in Zoetis in the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the 3rd quarter valued at about $31,000. Holos Integrated Wealth LLC purchased a new stake in Zoetis during the 4th quarter valued at about $32,000. Finally, Board of the Pension Protection Fund bought a new stake in Zoetis during the 4th quarter valued at about $38,000. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research note on Thursday, December 18th. Piper Sandler reissued a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Price Performance

ZTS opened at $115.43 on Friday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock has a market capitalization of $48.73 billion, a P/E ratio of 19.17, a P/E/G ratio of 1.77 and a beta of 0.95. The company’s 50-day simple moving average is $124.35 and its two-hundred day simple moving average is $130.44. Zoetis Inc. has a 52-week low of $114.36 and a 52-week high of $172.23.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the firm posted $1.40 EPS. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.